Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Depomed Acquires Rights to Cosyntropin from Slan Medicinal 11
Depomed Acquires Rights of Cebranopadol from Grunenthal 12
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 14
Depomed Acquires US And Canadian Rights To Cambia From Nautilus Neurosciences For US$53.7 Million 16
Depomed Acquires Lazanda Nasal Spray From Archimedes Pharma 17
Depomed Acquires Zipsor From Xanodyne Pharma 18
Licensing Agreements 20
Collegium Pharma Enters into Licensing Agreement with Depomed 20
Depomed Enters Into Licensing Agreement With Janssen Pharma 21
Equity Offering 22
Depomed Plans to Raise up to USD300 Million in Public Offering of Securities 22
Depomed Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Debt Offering 24
Depomed Raises USD345 million in Public Offering of 2.5% Notes Due 2021 24
Asset Transactions 26
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 26
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 27
Assertio Therapeutics Inc – Key Competitors 29
Assertio Therapeutics Inc – Key Employees 30
Assertio Therapeutics Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 08, 2018: Depomed announces second-quarter 2018 financial results 32
May 10, 2018: Depomed Announces First-Quarter 2018 Financial Results 34
Feb 27, 2018: Depomed Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 07, 2017: Depomed Announces Third Quarter 2017 Financial Results 37
Aug 07, 2017: Depomed Announces Second Quarter 2017 Financial Results 38
May 09, 2017: Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value 39
Feb 21, 2017: Depomed Reports Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 42
Oct 29, 2018: Assertio Therapeutics appoints Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018 42
Jun 05, 2018: Depomed Appoints Phillip B. Donenberg As Chief Financial Officer 43
Apr 17, 2018: Depomed Named John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications 44
Apr 17, 2018: Depomed Announces Appointment Of John B. Thomas As Senior Vice President, Investor Relations And Corporate Communications 45
Apr 02, 2018: Depomed Announces the Appointment of Stan Bukofzer as Senior Vice President and Chief Medical and Scientific Officer 46
Oct 18, 2017: Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Officer 47
Apr 25, 2017: Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration 48
Other Significant Developments 49
Aug 15, 2018: Depomed announces corporate name change to Assertio Therapeutics 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Depomed Acquires Rights to Cosyntropin from Slan Medicinal 11
Depomed Acquires Rights of Cebranopadol from Grunenthal 12
Depomed Acquires US Rights to Nucynta Franchise from Janssen Pharma for USD1.05 Billion 14
Depomed Acquires US And Canadian Rights To Cambia From Nautilus Neurosciences For US$53.7 Million 16
Depomed Acquires Lazanda Nasal Spray From Archimedes Pharma 17
Depomed Acquires Zipsor From Xanodyne Pharma 18
Collegium Pharma Enters into Licensing Agreement with Depomed 20
Depomed Enters Into Licensing Agreement With Janssen Pharma 21
Depomed Plans to Raise up to USD300 Million in Public Offering of Securities 22
Depomed Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Depomed Raises USD345 million in Public Offering of 2.5% Notes Due 2021 24
PDL BioPharma Acquires Remaining 50% Stake in Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 26
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 27
Assertio Therapeutics Inc, Key Competitors 29
Assertio Therapeutics Inc, Key Employees 30
Assertio Therapeutics Inc, Subsidiaries 31
List of Figures
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Assertio Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9